Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination therapy for liver cancer

Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination therapy for liver cancer

US Patent 10960017 · Granted Mar 30, 2021

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Base-modified cytidine nucleotides for leukemia therapy2025
Base-modified cytidine nucleotides for leukemia therapy2025
Base-modified cytidine nucleotides for leukemia therapy2025
Methods for treating liver cancers using an orally administered dioxolane nucleo2025
Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides2025
Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides2025
Dioxolane analogues of uridine for the treatment of cancer2022
Dioxolane analogues of uridine for the treatment of cancer2022
Dioxolane analogues of uridine for the treatment of cancer2022
Dioxolane analogues of uridine for the treatment of cancer2020
Dioxolane analogues of uridine for the treatment of cancer2020
Dioxolane analogues of uridine for the treatment of cancer2020